FDA approves Enzon's IND for cancer therapy

The FDA has approved Enzon Pharmaceuticals' IND for its HIF-1 alpha antagonist for various cancer types, including common solid tumors. The company plans to initiate a Phase I trial in the first half of 2007. "This marks an important milestone for Enzon as we continue to focus our efforts on important oncology therapies," said Jeffrey Buchalter, chairman and chief executive officer of the company. "The continued advancement of the HIF-1 alpha program demonstrates our commitment to developing a differentiated cancer portfolio."

- check out the press release for more

ALSO: Denmark's Santaris Pharma won a $5 million milestone from the acceptance of the IND. Release

Related Articles:
Santaris inks $200M collaboration with Enzon. Report